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ChromatographyThe ubiquitous sarco(endo)plasmic reticulum (SR/ER) Ca2+ ATPase (SERCA2b) and secretory-pathway Ca2+
ATPase (SPCA1a) belong both to the P2A-type ATPase subgroup of Ca
2+ transporters and play a crucial role in
the Ca2+ homeostasis of respectively the ER and Golgi apparatus. They are ubiquitously expressed, but their
low abundance precludes puriﬁcation for crystallization. We have developed a new strategy for puriﬁcation of
recombinant hSERCA2b and hSPCA1a that is based on overexpression in yeast followed by a two-step afﬁnity
chromatography method biasing towards properly folded protein. In a ﬁrst step, these proteins were puriﬁed
with the aid of an analogue of the SERCA inhibitor thapsigargin (Tg) coupled to a matrix. Wild-type (WT)
hSERCA2b bound efﬁciently to the gel, but its elution was hampered by the high afﬁnity of SERCA2b for Tg.
Therefore, a mutant was generated carrying minor modiﬁcations in the Tg-binding site showing a lower
afﬁnity for Tg. In a second step, reactive dye chromatography was performed to further purify and concentrate
the properly folded pumps and to exchange the detergent to one more suitable for crystallization. A similar
strategy was successfully applied to purify WT SPCA1a. This study shows that it is possible to purify
functionally active intracellular Ca2+ ATPases using successive thapsigargin and reactive dye afﬁnity
chromatography for future structural studies. This article is part of a Special Issue entitled: 11th European
Symposium on Calcium.opean Symposium on Calcium.
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Members of the superfamily of P-type ATPase actively transport
speciﬁc ions across various biological membranes with the use of
energy derived from ATP hydrolysis. Archetypical members of this
superfamily are the (α1 subunit of the) Na+/K+-ATPase and the sarco
(endo)plasmic reticulum (SR/ER) Ca2+ ATPase SERCA1a, i.e., two
highly specialized ion transporters that, because of their unusuallyhigh abundance, were the ﬁrst to be puriﬁed for crystallization [1,2].
In the last decade, more than 20 different crystal structures
representing nine different conformational states have been reported
for SERCA1a that together cover nearly the entire reaction cycle
providing detailed insights in the Ca2+ pumping mechanism [3–5].
However, because SERCA1a is present only in the highly specialized
SR of fast-twitch skeletal muscle, this isoform can hardly be
considered as the typical intracellular Ca2+ pump.
The structure–function of the housekeeping Ca2+ pumps found in
the intracellular compartments, i.e., the paraloguous SERCA2b and the
secretory-pathway Ca2+ ATPase SPCA1a are only poorly understood.
So far, due to their low tissue expression, these proteins evaded
puriﬁcation, which is required for more extensive functional charac-
terization and crystallization. Both pumps belong to the P2A-type
ATPase subgroup and transport Ca2+ ions back into the major
intracellular Ca2+ stores, respectively, the ER and the Golgi apparatus
[4]. These pumps help to maintain a low cytosolic Ca2+ concentration
in most cell types, but they also maintain the high luminal Ca2+
concentration required for vital cell functions, such as protein folding,
cell division and signaling [6].
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possess two high-afﬁnity Ca2+-transport sites (site I and site II).
Consequently, they can transport two Ca2+ ions per ATP hydro-
lyzed, whereas the SPCAs transport only one Ca2+ ion (binding to a
site corresponding to site II of SERCA). Despite this important
functional difference between SERCAs and SPCAs, their overall
sequence similarity clearly demonstrates a close relation (29%
sequence identity). Both types of Ca2+ pumps cycle between two
major conformations: E1, with the high-afﬁnity Ca2+-binding site(s)
facing the cytoplasm, and E2, in which the same Ca2+-binding site
(s) lower their afﬁnity for the ion and reorient to the organellar
lumen [7,8].
The housekeeping SERCA2b pump markedly differs from other
SERCA isoforms by an extra 11th transmembrane (TM) region and
luminal C-terminus. Based on extensive mutagenesis, a structural
model of SERCA2b was recently developed, predicting intramolecular
interactions of the 2b tail with upstream regions of the pump (i.e.,
within the membrane and in the ER lumen). This interaction would
stabilize the pump in the E1 conformation, which at least partially
explains its higher apparent afﬁnity for Ca2+ [9,10]. Solving the crystal
structure of SERCA2b might provide additional support for these
structural and functional predictions. Thereto, the protein needs to be
puriﬁed from an overexpression system such as Saccharomyces
cerevisiae. Related P-type ATPases like SERCA1a, H+-ATPase and
PfATP6 were already successfully overexpressed in yeast for puriﬁca-
tion [11–15]. In a previously described method, a biotin acceptor
domain (BAD)-tag attached at the C-terminus of the protein was used
to purify recombinant SERCA1a from yeast by means of streptavidin
afﬁnity chromatography [16]. The presence of a tag at the C-terminus
may ensure that only full-length expressed proteins are puriﬁed.
However, based on the SERCA2b structural predictions, a C-terminal
tag would interfere with proper docking of the 2b tail to the luminalFig. 1. 3-Dimensional view of the SERCA1a and its thapsigargin-binding site. The 3-dimensio
SERCA inhibitor thapsigargin (Tg). The Tg-binding site is indicated by the triangle (A). Tilted
residues contributing to the binding site are depicted in stick representation.side of the pump [10]. Therefore, the BAD systemor related approaches
using other afﬁnity tags could only be used when attaching the tag to
the N-terminus, where it not necessarily allows the selection of
correctly translated and folded proteins.
In this study, we describe a new afﬁnity puriﬁcation strategy based
on thapsigargin (Tg), which avoids the use of afﬁnity tags and
guarantees the puriﬁcation of properly folded ATPases. Tg is a
sesquiterpene lactone derived from the plant Thapsia garganica [17],
which inhibits SERCA in the sub-nanomolar range such that it fully
blocks SERCA activity in almost stoichiometric amounts [18]. It binds
to SERCA in a hydrophobic, funnel-like cavity open to the cytosol
formed by TM3, TM5 and TM7 and prevents the movement of the
helices relative to each other (Fig. 1). This explains the inhibitory
effect on the pump [19]. Because amino acids lining the binding
pocket for Tg in SERCA1a are fully conserved in SERCA2b, the crystal
structure of SERCA1a is highly informative regarding the Tg-binding
site in SERCA2b. Note that SPCA1 also shows some sensitivity toward
Tg inhibition, but in a Tg concentration range of at least 1000-fold
higher (still micromolar) compared to SERCA [20].
Here, we report a proof of principle of a novel technique for afﬁnity
puriﬁcation of properly folded SERCA2 and SPCA1 from a yeast
overexpression system using Tg and ATP analogues (respectively Tga,
i.e., 2–12 ADT, and reactive dye). This method will enable future
crystallization attempts of these housekeeping pumps.
2. Materials and methods
2.1. Heterologous expression of human SERCA2b and SPCA1a in
yeast cells
The human (h) SERCA2b and SPCA1a cDNAswere ampliﬁed by PCR
and cloned by Gateway (Invitrogen) recombination in a custom-madenal structure of SERCA1a (2AGV [46]) is shown in the E2 conformation stabilized by the
and enlarged view of the Tg-binding site, ﬂanked by TM3, TM5 and TM7 (B). Important
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alcohol dehydrogenase 2 (ADH2) promoter [21]. Mutants of hSERCA2b
and hSPCA1a were generated by PCR based on the QuickChange site-
directed mutagenesis strategy (Stratagene). S. cerevisiae cells (strain
BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0)) were transformed
with the pTV001E vector containing hSERCA2b or hSPCA1a wild-type
(WT) or mutants by the protocol developed by Gietz and Schiestl [22].
Transformed yeast cellswere then transferred ontominimummedium
(MM) plates (0.67% yeast nitrogen base without amino acids, 0.154%
yeast drop-outmixwithout tryptophane and leucine, 2% glucose, 8 μg/
ml tryptophane, 1.5% agar) and incubated for 48 h. This MM is
deprived of leucine. Because S. cerevisiae is auxotrophic for leucine,
only those cells that acquired the plasmid containing the auxotrophy
marker synthesized leucine and grew on MM.
2.2. Selection of individual clones in MM
A colony on aMMagar platewas tooth-picked into 5 ml ofMM and
grown for 24 h. Preparation of total protein extracts was based on the
protocol of Riezman et al. [23] slightly modiﬁed as described in
Volland et al. [24]. These samples were analyzed by Western blotting
to select the best clones. Stocks of the MM precultures of these clones
were stored in the form of colonies on MM agar plates or as 20%
glycerol samples stored at −80 °C.Fig. 2. Synthesis of2.3. Yeast expression
First, 10 ml of MM was inoculated with the selected clone. After
24 h of growth, the preculture was used to inoculate a fresh 100 ml of
MM. After another 24 h, the second preculture was used to inoculate
500 ml of YPD medium at 0.1 OD. When the yeast culture entered the
exponential growth phase glucose became slowly converted to
ethanol. The rise in ethanol concentration induced the ADH2 promoter
and our protein of interest was expressed [21]. The optimal biomass
and optimal SERCA2b expression (data not shown) was reached after
30 h of growth. The cultures were centrifuged for 10 min at 5000×g at
4 °C. The pellet was washed with cold H2O, centrifuged again,
weighed (wp), ﬂash-frozen and stored at −20 °C.
2.4. Preparation and solubilization of yeast microsomes
Microsomes were prepared and solubilized as described by
Jidenko et al. [16]. Microsomes were diluted into the same
solubilization buffer at a protein concentration of 10 mg/ml and
with a detergent to protein ratio of 3:1 (w/w) (detergent n-
dodecyl β-D-maltoside (DDM), Anatrace). The suspension was gently
stirred for 15 min before centrifugation for 45 min at 160,000×g at
4 °C. Protein concentration was determined with the Bradford assay
[25].compound 1.
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The synthesis of compound 1 (Fig. 2)was based on the availability of
the ketal 2 [26,27] and phtalimidododecanoate [28]. Dicyclohexylcar-
bodiimide (DCC) provoked acylation of compound 2with compound 3
using 4-dimethylaminopyridine (DMAP) as a catalyst afforded 4, in
which the ketal was cleaved with hydrochloric acid (compound 5).
Selective acylation at O8 with butyric anhydride catalyzed with DMAP
afforded compound 6, which selectively was acylated at O10 using
isopropenyl acetate as a reagent (compound 7) [26]. Finally, the
phtalimido group was replaced with Boc using hydrazine (compound
1: 2–12 ADT). A detailed description of the synthesis and spectral data
for the prepared compounds is given in Appendix A.
2.6. Tg analogue coupling
Removal of the tert-butyloxycarbonyl (Boc) group from Boc-Tg
analogue (2–12 ADT)was accomplished by treatment of the protected
analogue with triﬂuoroacetic acid (TFA) in anhydrous acetonitrile
(AcCN) (Fig. 3A). Immediately after decoupling of the Boc group, as
conﬁrmed by a positive ninhydrin reaction and thin layer chromatog-Fig. 3. Reaction scheme of Tg analogue coupling to NHS-activated Sepharose beads. Reaction
Removal of the tert-butanoyl group of Boc-Tga by triﬂuoroacetic acid (TFA). B. Coupling of dep
Side product of the reaction, i.e., N-hydroxy-succinimide (NHS).raphy, the mixture was lyophilized to remove the aggressive TFA. The
free primary amine group on the Tga now allowed its attachment to
N-hydroxysuccinimide (NHS)-activated Sepharose beads (Sepharose
4 Fast Flow, GE Healthcare). Sepharose beads were equilibrated for
immobilization by washing themwith cold 1 mMHCl. The lyophilized
decoupled Tga was dissolved in 50% AcCN and 50% coupling buffer
(0.2 M NaHCO3, 0.5 M NaCl, pH 7.5) and gently mixed with the
activated NHS Sepharose beads at room temperature for 1 h (0.2 μmol
of Tga/100 μl of NHS Sepharose beads) (Fig. 3B). The completeness of
the reactionwas checked photometrically bymonitoring the release of
NHS at 260 nm (Fig. 3D). Residual active groups on the Sepharose
beadswere blockedwith 0.5 M ethanolamine and 0.5 MNaCl (pH 7.5),
afterwhich the beadswerewashed alternatelywith 0.1 MTris–HCl pH
7.5 and 0.1 M Na-acetate, 0.5 M NaCl (pH 5.5). The Tga-coupled
Sepharose beads (Fig. 3C) were stored in AcCN at 4 °C.
2.7. Tga-afﬁnity puriﬁcation
Before loading the solubilized yeastmicrosomes on the Tga-afﬁnity
column, the column was washed with 2 column volumes (Vcolumn) of
equilibration buffer (20% glycerol, 100 mM Tris pH 7.5, 100 mM NaCl,scheme of the coupling of the Tg analogue (Tga) to NHS-activated Sepharose beads. A.
rotected Tga to activated NHS Sepharose beads. C. Tga-coupled NHS Sepharose beads. D.
Fig. 4. Different puriﬁcation steps of the Tga-afﬁnity procedure for WT hSERCA2b.
Western blotting of different fractions of the Tga-afﬁnity puriﬁcation ofWT hSERCA2b is
shown. 5 μl of in total 100 μl (5%) beads and 8 μl out of 200 μl (4%) of other fractions (S,
FT, W and E) are loaded. Besides samples of the relevant liquid fractions also samples of
the Tga-Sepharose beads before elution (BB) are compared with the beads after elution
(BE) to estimate the %release of the ATPase. M:marker; S: sample; FT: ﬂow-through;W:
wash step; E: elution step.
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detergent (10 mg/ml DDM). The extract was applied to the column
and was allowed to equilibrate in batch on a shaking table for 1 h at
4 °C. After binding, the column was washed with 5 Vcolumn of wash
buffer 1 (20% glycerol, 100 mMTris pH 7.5, 100 mMNaCl, 5 mMEGTA,
1 mMDTT, 5 mg/mlDDM) and3Vcolumn ofwash buffer 2 (20% glycerol,
100 mM Tris pH 7.5, 5 mM EGTA, 1 mM DTT, 1 mg/ml DDM). The P2A-
type Ca2+ ATPases were eluted from the Tg column with 2 Vcolumn of
elution buffer (20% glycerol, 100 mM Tris pH 7.5, 1 mM MgCl2, 1 mM
DTT, 10 mg/ml DDM, 10 mM CaCl2, 100 μM Tg (Sigma)), upon which
the Tg column was quickly regenerated with 5 Vcolumn of cleaning
buffer (20% glycerol, 100 mMTris pH 7.0, 0.5 mMEDTA, 5% SDS) and 5
Vcolumn of equilibration buffer. The column was stored at 4 °C in AcCN.
2.8. Reactive blue afﬁnity puriﬁcation
Reactive blue (RB) 4 (Sigma) agarose was washedwith 5 Vcolumn of
water and equilibrated with 1 Vcolumn of equilibration buffer RB
(8 mg/ml DDM, 2.5 mg/ml phosphatidylcholine (PC), 8 mM CaCl2,
50 mM Tris pH 7.5, 5 mM DTT, 20% glycerol). The elution fractions
from the Tga-afﬁnity puriﬁcation were applied to the RB agarose
beads. To optimize binding, proteins were incubated with the RB
agarose for a minimum of 30 min in batch on a shaking plate, after
which the gel was washed with 2 Vcolumn of wash buffer RB (1 mg/ml
C12E8 (octaethylene glycol monododecyl ether), 0.35 mg/ml PC, 1 mM
CaCl2, 20 mM Tris pH 7.5, 1 mM DTT, 20% glycerol). The ATPases were
released from the RB columnwith 2 Vcolumn of elution buffer RB (wash
buffer+50 mMNaCl, 4 mM β,γ-methyleneadenosine 5′-triphosphate
disodium salt (AMPPCP)). After elution, the RB agarose was washed
with 5 Vcolumn of cleaning buffer RB 1 (1 MNaCl, 0.1 M borate–HCl, pH
9.8) and 5 Vcolumn of cleaning buffer RB 2 (0.1 M borate–HCl, pH 9.8).
The RB gel was stored in 2 M NaCl at 4 °C.
2.9. Gel staining and Western blotting
Protein samples were loaded on NuPageTM bis–Tris 4–12% gradient
gels (Invitrogen). Samples containing Sepharose beads were boiled for
5 min to release proteins from the beads. After electrophoresis, the
separated proteins were visualized in the gel by ﬂuorescent Sypro
Orange staining (Invitrogen). Alternatively, the separated proteins on
the gel were transferred to Immobilon-P membranes for Western
blotting [29]. Rabbit polyclonal antibodies against hSERCA2b (1:10,000)
[30] or against hSPCA1 (Frodo Ab, 1:40,000) [31] were applied.
2.10. Protein identiﬁcation by mass spectrometric analysis
The bands of interest were excised from the SDS gel and subjected
to overnight digestion at 37 °C with 250 ng of trypsin in 100–200 μl of
200 mM ammonium bicarbonate. The resulting peptides were
extracted as described [32], and the extract was concentrated and
desalted with ZipTip C18 (Millipore, Bedford, MA, USA) and analyzed
by MS/MS on a MALDI-TOF/TOF mass spectrometer (Applied
Biosystems 4800 Proteomics Analyzer) using α-cyano 4-hydroxycin-
namic acid as a matrix (5 mg/ml solution in 50% AcCN and 0.1% TFA in
HPLC water). Data interpretation was carried out using the GPS
Explorer software (Version 3.5), and database searching was carried
out using the Mascot program (Version 2.2) [32].
2.11. Formation of the phosphoenzyme intermediate
Control microsomes containing hSERCA2b WT (0.5 μg micro-
somal proteins) or puriﬁed samples containing hSERCA2b-I765A
(0.5 μg) were phosphorylated as previously described [33]. 100 nM
Tg or 100 μM CaCl2 was added to respectively inhibit or activate the
SERCA pumps. Phosphorylated proteins were separated by acid 7.5%
SDS-PAGE gel system according to Sarkadi et al. [34]. After ﬁxationof the gels in 7.5% acetic acid, they were dried between sheets of gel
drying ﬁlm (Promega) and exposed to a PhosphorImager™ screen
(GE healthcare) for quantiﬁcation.
3. Results
3.1. Puriﬁcation of hSERCA2b
3.1.1. Tga-afﬁnity puriﬁcation of recombinant hSERCA2b WT
Previously, yeast was successfully employed to express recombi-
nant SERCA1a [11,13] or the plant proton pump [14].We now adapted
this procedure for puriﬁcation of SERCA2b. We thereto transformed S.
cerevisiae with the pTV001E vector containing the full-length open
reading frame of humanWT SERCA2b cDNA. Yeast was then grown in
large quantities; after homogenization, microsomes were prepared.
Microsomal membranes containing hSERCA2b were solubilized with
DDM detergent and, prior to application on a Tga-afﬁnity gel, diluted
in equilibration buffer to a ﬁnal concentration of 2 mg of protein/ml.
Because Tg binds to the Ca2+-free E2 conformation of the ATPase [35],
5 mM of EGTA was added to the extract to remove all Ca2+ and force
the pump in an E2 conformation. Since the absence of Ca2+
destabilizes the ATPase, in particular if the protein is detergent-
solubilized [36], the chelator was only administered immediately
prior to afﬁnity chromatography.
The bound hSERCA2bwas released in the presence of 10 mM CaCl2
to convert the enzyme back to E1, whichwould disrupt the Tg-binding
site. The buffer was supplemented with 100 μM Tg as a soluble
competitor for the immobilized Tga. Fig. 4 shows that WT hSERCA2b
binds to the Tga-afﬁnity column, but not entirely unexpected, this
binding is so tight that hardly any ATPase can be eluted (Fig. 4E1–E5).
Most likely, this is related to the high afﬁnity of SERCA2b for Tg
(inhibitor concentration to generate 50% inhibition of SERCA2b
activity Ki=1.3 nM) [37]. To more directly assess the amount of
ATPase bound to the afﬁnity gel, samples of the beads were analyzed
and bound ATPase was quantiﬁed by Western blotting both before
(BB) and after (BE) the elution steps. This analysis allows amore direct
estimation of the fractional release of the pump, which amounted to
maximally 30% for WT hSERCA2b.
3.1.2. Tga-afﬁnity puriﬁcation of hSERCA2b mutated in its Tg-binding site
The intrinsically very strong binding to Tga-Sepharose hampers the
elution of WT hSERCA2b from the Tga column. To circumvent this
problem, we aimed to moderate hSERCA2b's afﬁnity for this ligand by
site-directed mutagenesis of its Tga-binding pocket (formed by
transmembrane regions TM3, TM5 and TM7 (Fig. 1A)). The choice of
mutations was directed by a previous study of Xu et al. [38] that
reported SERCA1a mutations F256L, I765A and Y867A with a reduced
Fig. 5. Puriﬁcation steps of the Tga-afﬁnity procedure for hSERCA2b mutants. Western blotting of different fractions of the Tga-afﬁnity puriﬁcation of hSERCA2b-F256L (A),
hSERCA2b-Y837A (B) and hSERCA2b-I765A (C) is shown. 5 μl of 100 μl (5%) beads and 8 μl out of 200 μl (4%) of other fractions (S, FT, W and E) are loaded. The Tga-Sepharose beads
before elution (BB) are compared with the beads after elution (BE) to estimate the %release of the enzyme. M: marker; S: sample; FT: ﬂow-through; W: wash step; E: elution step.
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SERCA1a (Ki=1.4 nM) [38]. Since the Tg-binding site is completely
conserved between SERCA1a and SERCA2b, we expect a similar effect
of these mutations in the hSERCA2b background. Three hSERCA2b
mutants were created by site-directed mutagenesis. Mutating the
F256 residue to L (hSERCA2b-F256L mutant) lowered the binding to
the Tga beads (Fig. 5A). The fractional release was estimated around
10%. These results therefore conﬁrm the critical role of F256 for Tg
binding [37,38]. hSERCA2b-Y837A and hSERCA2b-I765A (Fig. 5B, C)Fig. 6. Screening for optimal elution conditions of hSERCA2b-I765A. Protein gel staining by Syp
acid of hSERCA2b-I765A in high (10 μg/μl) and low (1.5 μg/μl) detergent concentrations and
using the SERCA2b antibody to demonstrate SERCA-speciﬁc staining in the fractions of hSERC
M:marker;W:wash step; E: elution step. 1: Pma1; 2: Hsp75; 3: Hsp71; 4: Ef1a; 5: Erv46; 6: H
staining: 200 μl of every fraction is precipitated with TCA and loaded on the gel. For Westercan be more easily released from the Tga matrix than WT hSERCA2b.
The fractional release was ~50% and ~90%, respectively, compared to
at most 30% for WT hSERCA2b.
3.1.3. Optimization of the Tga-afﬁnity puriﬁcation of the
hSERCA2b-I765A mutant
The hSERCA2b-I765A mutant was selected as the most suitable
candidate for further puriﬁcation. Importantly, this mutation did only
affect the afﬁnity for Tg, with no observed effect on the overallro Orange. Gel is loadedwith different elution fractions precipitatedwith trichloroacetic
with 10 mM CaCl2 and 100 μM Tg (A) or with 10 mM CaCl2 alone (B). Western blotting
A2b-I765A eluted with 10 mM CaCl2 and 100 μMTg (C) or with 10 mM CaCl2 alone (D).
sp 42; 7:Vdac1. Dotted line: separation line indicating different gels or blots. For the gel
n blotting: 5% of the beads and 4% of the other fractions (S, FT, W and E) are loaded.
Fig. 7. Elution of hSERCA2b-I765A from the RB-afﬁnity column. A. Sypro Orange
staining of the eluted fractions (E1–E4) from the RB-afﬁnity column shows one clear
band containing hSERCA2b-I765A (E2–E4). Some contaminants and hSERCA2b-I765A
are clearly bound to the RB beads (BB). After elution with 2 Vcolumn wash buffer
supplemented with 4 mM AMPPCP and 50 mM NaCl the contaminants and some
residual SERCA2b mutant remain bound to the RB beads (BE). M: marker. 5% of the
beads and 20% of the elution fractions are loaded. B. Western blotting of the eluted
fractions (E2–E4) with the SERCA2b antibody conﬁrming that our eluted protein is
indeed the SERCA2b mutant. 1 μl of eluted fractions is loaded. C. Phosphorylation
experiment in the presence of the inhibitor Tg or activator Ca2+ conﬁrmed that our
puriﬁed hSERCA2b-I765A is still active. 1 and 2: Control samples containing COS
microsomes with hSERCA2b WT (prepared as previously described [10]). 3 and 4:
Puriﬁed hSERCA2b-I765A.
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structural changes of the pump. The elution of the hSERCA2b-I765A
mutant from the Tga columnwas compared in high (10 mg/ml) or low
(1.5 mg/ml) DDMdetergent concentrations (Fig. 6). Elution by 10 mM
CaCl2 and 100 μM Tg in low detergent yielded an elution fraction E1
(i.e., the ﬁrst fraction collected, corresponding to 2 column volumes
(Vcolumn)) in which hSERCA2b-I765A represented about 65% of the
total protein (Fig. 6A). With increasing detergent concentration in the
elution buffer, more contaminants were co-eluted and the SERCA/
total protein ratio decreased to 30% (Fig. 6A). We were surprised to
ﬁnd that omission of Tg from the elution buffer actually improved the
yield of SERCA. However, the purity of the SERCA sample was lower.
Most likely, the DMSO vehicle used to dissolve the Tg in the elution
buffer suppressed the yield of SERCA. It has already been reported by
Engelender and De Meis [39] that around 10% DMSO has the ability to
antagonize the effect of compounds like triﬂuoperazine. This DMSO
concentration is in the same range as that we are working with.
Therefore, DMSO was omitted, which is also beneﬁcial for future
studies. The highest yield of total SERCA was thus obtained with an
elution buffer containing 10 mg/ml DDM and 10 mM CaCl2, but
without added Tg.
Note that the absence of Tg from the elution buffer would allow
future functional measurements and of particular interest, also the
crystallization of SERCA2b in the E1 conformation, a condition that
requires the presence of Ca2+ but absence of Tg. The SERCA2b tail
would only interact with its binding pocket in the E1 conformation
[10].
The yeast proteins contaminating our puriﬁed preparation were
determined by mass spectrometry, and the fragment sizes were
compared with a yeast protein fragment database. The contaminants
were identiﬁed as heat-shock proteins (Hsp71, −75 and −42), the
plasmamembrane proton pump (Pma1), elongation factor 1-α (Ef1-α),
ER-derived vesicles protein (Erv46) and the voltage-dependent anion-
selective channel protein 1 (Vdac1) (Fig. 6).
A second afﬁnity puriﬁcation step was applied to serve the triple
purpose of (1) removing the contaminants, (2) concentrating SERCA,
(3) decreasing and exchanging the DDM detergent for C12E8 because
the latter detergent is more suitable for crystallization [40,41]. When
upscaling the Tga-afﬁnity puriﬁcation procedure prior to the second
afﬁnity puriﬁcation step, the detergent (DDM) concentration was
lowered to 8 mg/ml and egg yolk PC was added at a concentration of
2.5 mg/ml to increase stabilization of the ATPase.
3.1.4. Reactive blue puriﬁcation
As a second puriﬁcation step, reactive dye afﬁnity chromatography
was considered [42]. This ligand is actually a textile dye, which
mimics a natural ATP ligand. In this form of pseudo afﬁnity
chromatography, the dye serves as an inexpensive and stable
alternative for the true afﬁnity ligand. Reactive red (RR) attached to
agarose beads can be used to purify ATPases [43] and has been
successfully applied to the muscle isoforms SERCA1a [2,44] and
SERCA2a [45]. We screened different reactive beads (corresponding
to different ATP analogues) for their potential to purify SERCA2b (data
not shown). To that end, the eluate of the Tga-afﬁnity column
containing hSERCA2b-I765A was incubated with RR, reactive green
(RG) and reactive blue (RB) agarose beads. The SERCA2b mutant was
found to bind only to RR and RB beads and not to RG. Contrary to what
is described for the muscle isoforms SERCA1a [2,44] or SERCA2a [45],
we failed to elute the SERCA2b mutant from the RR beads (data not
shown). Fortunately, elution of the RB column with 4 mM AMPPCP
and 50 mM NaCl added to the wash buffer yields a pure sample
containing hSERCA2b-I765A (Fig. 7). Note that the RB puriﬁcation
step allows exchange of the DDM detergent, which is optimal for
solubilization of yeast membrane proteins [11], with C12E8 detergent,
which is superior for crystallization of hydrophobic membrane
proteins [40,41].200 ml of yeast culture yields around 3 g of yeast biomass and
around 20 mg of microsomes. Tandem-afﬁnity puriﬁcation on a 5-ml
Tga column followed by a 100 μl RB column yields 15 μg of pure
hSERCA2b-I765A. Protein concentration of one elution fraction (E3,
Fig. 7A) was estimated with the Bradford protocol at 0.1 mg/ml.
Puriﬁed proteins were analyzed by Mass Spectrometry, Western
blotting (Fig. 7B) and phosphorylation (Fig. 7C) conﬁrming that we
obtained pure and functionally active hSERCA2b-I765A. Thus, we
successfully established a novel method to selectively purify a
hSERCA2b mutant with a mild mutation in its Tg-binding site.
3.2. Tga puriﬁcation of hSPCA1a
To explore whether the same puriﬁcation strategy could be
applied to SPCA1a, a related P2A-type Ca2+ pump, showing a 1000-
fold lower afﬁnity for Tg (Ki=28 μM [20]), a human SPCA1 homology
model was ﬁrst developed based on the rabbit (r) SERCA1a E2
structure (1IWO [46]) using the MODELLER program [47] (Fig. 8) [4].
hSPCA1a shows 29% overall sequence identity and 43% similarity with
the rSERCA1a isoform. Due to internal deletions, the hSPCA1 sequence
is shorter than rSERCA1, which is reﬂected in shorter cytosolic and
luminal loops (Fig. 8A vs. Fig. 1A) [4]. Because the N- and C-termini of
hSPCA1 poorly align with those of SERCA, they were excluded from
the input to the modeling program. The hSPCA1 homology model
applies to all human SPCA1 isoforms, which only differ in their
C-termini [4]. A closer view at the Tg-binding site (Fig. 8B) revealed a
similar funnel-like cavity as in the rSERCA1a structure, in agreement
with an at least moderate sensitivity of SPCA for Tg (Fig. 1B vs. 8B).
However, at the residue level, the site clearly differs, which might
explain the 1000-fold lower afﬁnity for Tg compared to SERCA1a [20].
Fig. 9. Different steps of the Tga-afﬁnity puriﬁcation procedure for WT hSPCA1a.
Western blotting of different fractions of the Tga-afﬁnity puriﬁcation of WT hSPCA1a.
BB: beads before elution; BE: beads after elution; M: marker; S: sample; FT: ﬂow-
through; W: wash step; E: elution step. 5% of the beads and 4% of the other fractions (S,
FT, W and E) are loaded.
Fig. 8. 3-Dimensional view of the hSPCA1a model and its Tg-binding site. hSPCA1a modeled on the rabbit SERCA1a structure in the E2 conformation (1IWO [46]) (A). The longer N-
and C-termini of hSPCA1a were left out the model. The Tg-binding site (B) is ﬂanked by TM3, TM5 and TM7. Residues of hSPCA1 that correspond to those contributing to the Tg-
binding site in SERCA are depicted in stick representation.
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hSPCA1a was efﬁciently bound to the Tga-afﬁnity gel and was readily
eluted with elution buffer containing 10 mM Ca2+. Moreover,
analyzing the bead samples before and after the elution steps
estimated the fractional release of this pump at nearly 60% (Fig. 9).
Although this Tga-afﬁnity column is not suitable for purifying WT
hSERCA2b due to its very high sensitivity towards Tg, the much lower
sensitivity of SPCA1a for this inhibitor makes this column very useful
to purify WT hSPCA1a.
4. Discussion
4.1. Towards a general method for purifying P2A-type Ca
2+ ATPases
Here, we describe a proof of principle of a novel method to purify
recombinant hSERCA2b or hSPCA1a from a yeast overexpression
system that is based on binding of properly folded protein to two
successive afﬁnity puriﬁcation columns. In the ﬁrst step, the ligand is a
Tga (2–12 ADT), a high-afﬁnity inhibitor of SERCA. Interestingly, since
this inhibitor also displays some afﬁnity for SPCA1a, we could also
successfully employ this strategy to SPCA1a. As a ligand for the second
step, we explored the use of various reactive dyes as ATP analogues. In
case of the SERCA2b form (hSERCA2b-I765A), reactive blue was found
optimal. This contrasts with SERCA1a (best reaction with RR/RG) and
SERCA2a (best with RG). Therefore, it seems that the various P-type
ATPases behave differently with respect to binding of various reactive
dyes, emphasizing the importance of reactive dye screening for P-type
ATPase puriﬁcation.
This new tandem afﬁnity puriﬁcation method offers four clear
advantages for the puriﬁcation of P2A-type ATPases. First, since the
binding to the afﬁnity ligands (thapsigargin and reactive dyes)
requires structurally intact domains, the method selects for properly
folded proteins, which is a prerequisite for downstream applications
such as functional assays or structure determination. Second, theprotocol does not rely on the use of afﬁnity tags, which might
interfere with the pump function and structure. Therefore, there is no
need for a post-puriﬁcation cleavage step. Third, the procedure is
generic in the sense that it can be applied to different P2A-type
ATPases provided that there is an intact Tg-binding site and that the
reactive dye binding is optimized. As such, it is the ﬁrst technique
described that can purify SPCA1a. Since the afﬁnity of the immobi-
lized Tga for SPCA was appropriate to allow both efﬁcient binding and
elution, there was no need to mutate the Tg-binding site for optimal
puriﬁcation. Fourth, the method takes advantage of the versatility of
the yeast system as an overexpression host for Ca2+ ATPases like
SERCA2b and SPCA1a. Notably, since yeast does not endogenously
express SERCA, contamination of our ﬁnal puriﬁed hSERCA2b
preparation with yeast-derived SERCA is not possible. The presence
of Pmr1 (the yeast orthologue of SPCA) cannot be fully excluded,
although mass spectrometry analysis of the strongest contaminants
did not indicate any major co-puriﬁcation of Pmr1.
Fig. 10. Two linker sites on Tg for chemical modiﬁcation (R1 and R2). 8-12ADT
represents the pro-drug used to treat prostate cancer, which is now in clinical trial
phase I [51,58], 2-12ADT represents the Tga used for afﬁnity puriﬁcation.
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the general applicability of this method. First, the non-hydrolysable
ATP analogueAMPPCP is used to elute SERCA from theRB gel. Although
it provides additional stabilization of the protein for crystallization, it
might interfere with subsequent functional assays [48]. Here,
phosphorylation was clearly observed demonstrating that SERCA2b
is still functional after puriﬁcation, but in the presence of AMPPCP, the
amount of detected phospho-intermediate is likely an underestima-
tion of the total amount of puriﬁed pumps. Second, our new
puriﬁcation method still requires further optimization and upscaling
of the protocol to increase the yield of puriﬁed Ca2+ ATPases, before
enough protein can be obtained for functional experiments or
crystallization attempts. Further concentration steps are possible.
4.2. Comparison with other puriﬁcation methods
An earlier described method to purify recombinant SERCA1a from
yeast involved the use of streptavidin-afﬁnity chromatography [16].
For that purpose, a biotin-acceptor domain (BAD) tag was cloned at
the C-terminus, a position that ensures the puriﬁcation of fully
translated proteins. We discarded the possibility to use this strategy
for the puriﬁcation of SERCA2b since a C-terminal tag would be in the
ER lumen and therefore not accessible to the biotinylation system.
Further, the presence of the tag would interfere with the binding of
the extreme C-terminus of SERCA2b to its luminal binding site,
presumably disturbing proper functioning of the pump [10]. Our
technique avoids the use of tags and ensures that only properly folded
pumps displaying a functional Tg site are puriﬁed.
4.3. Tg as a ligand for afﬁnity puriﬁcation of P2A-type Ca
2+ ATPases
Tg inhibits SERCA in the nanomolar range [18] and SPCA1 in the
micromolar range in contrast to other well-known inhibitors like
cyclopiazonic acid (CPA) [49] or 2,5-di(tert-butyl)hydroquinone
(DBHQ) [50], which inhibit SERCA in the micromolar range and
even SPCA in the millimolar range [4]. The high afﬁnity of Tg makes it
possible to successfully modify this molecule for coupling to a ligand
without compromising its afﬁnity for the pump. An interesting
example of this is its successful modiﬁcation to create a pro-drug
(8-12ADT, Fig. 10) for the treatment of cancer [51–55]. A structural
study of this Tg pro-drug has revealed that the ﬂexible dodecanoyl
side chain is adjusted between the transmembrane helices M3, M4,
and M5 [51,52,56]. The presence of a bead covalently bond to the
amino group would prevent the side chain from penetrating between
the helices. In contrast, the octanoyl group bound toO2 is found on the
surface of the pump. Based on that information, we therefore chose toattach the Sepharose beads at the O-2 position to avoid sterical
hindrance (Fig. 10).
The afﬁnity of the immobilized Tga for SERCA was so high that the
pumps once bound to the afﬁnity gel were very difﬁcult to release.
Minor mutations in the Tg-binding site of hSERCA2b were introduced
to decrease the afﬁnity for Tga to a workable range. The corresponding
mutations in SERCA1a do not disrupt pump function. Their only effect
is to moderately diminish Tg sensitivity [38]. Our results are in line
with previous reports on the critical role of F256 in Tg binding
[37,38,57]. F256 apparently strengthens the binding of Tg through
ring stacking of F256 with the seven-membered ring of Tg. Also in
agreement with previous studies [38], we conﬁrmed that I765 and
T837 are important for Tg binding but not essential for the normal
activity of the Ca2+ pump. Thus, although until now only mutants of
SERCA2b can be puriﬁed with the currently developed Tg-afﬁnity
matrix, there is a high probability that the structures of these Tg
SERCAmutantswill represent the physiological structure of the pump.
To reach the future goal of purifyingWT SERCA2b, i.e., with unaltered
Tg-binding sites, we are currently designing Tg analogues with reduced
afﬁnity for SERCA2b. Such novel analogues might allow SERCA2b
puriﬁcation from animal tissue. In this respect, an attractive source
would be the hearts of SERCA2b/b mice developed in our laboratory, in
which the highly abundant SERCA2a is replaced by SERCA2b. These hearts
represent the tissue with the highest known relative expression of
SERCA2b.
5. Conclusion
The yeast overexpression system was successfully adapted to
overexpress the P2A-type Ca2+ ATPases hSERCA2b (I765A mutant)
and hSPCA1a (WT). These mutants were then puriﬁed with a novel Tg
analogue, followed by reactive dye afﬁnity puriﬁcation. This method
provides highly puriﬁed Ca2+ ATPases, which will be very valuable for
future structural and functional studies.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2010.12.020.
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